K. Cody

发表

Amyloid duration is associated with preclinical cognitive decline and tau PET

Sterling C. Johnson, B. Christian, R. Koscik, 2020, Alzheimer's & dementia.

Amyloid duration is associated with preclinical cognitive decline and tau PET

Sterling C. Johnson, B. Christian, R. Koscik, 2019, bioRxiv.

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.

R. Sperling, M. Greicius, I. Cobos, 2022, JAMA neurology.

Assessment of vascular stiffness in the internal carotid artery proximal to the carotid canal in Alzheimer’s disease using pulse wave velocity from low rank reconstructed 4D flow MRI

Sterling C. Johnson, Kevin M. Johnson, H. Rowley, 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls

Sterling C. Johnson, Matthew D. Zammit, B. Christian, 2018, The Journal of Nuclear Medicine.

Sympathoexcitatory Responses to Isometric Handgrip Exercise Are Associated With White Matter Hyperintensities in Middle-Aged and Older Adults

Sterling C. Johnson, K. Cody, N. Chin, 2022, Frontiers in Aging Neuroscience.

Plasma pTau-217 in preclinical Alzheimer's disease

J. Tobey, O. Hansson, E. Jonaitis, 2022, medRxiv.

Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome

Sterling C. Johnson, Matthew D. Zammit, W. Klunk, 2020, Neurobiology of Aging.

Amyloid accumulation in Down syndrome measured with amyloid load

Sterling C. Johnson, Matthew D. Zammit, D. Minhas, 2020, Alzheimer's & dementia.

Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer's Prevention

Sterling C. Johnson, Victoria J. Williams, Kimberly D. Mueller, 2022, Alzheimer's & dementia.

Trajectory of clinical symptoms in relation to amyloid chronicity

Sterling C. Johnson, R. Koscik, E. Jonaitis, 2022, Alzheimer's & dementia.

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study

Sterling C. Johnson, K. Blennow, O. Hansson, 2022, medRxiv.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

Sterling C. Johnson, Alexa Pichet Binette, K. Blennow, 2022, Nature Medicine.

White matter microstructure associations to amyloid burden in adults with Down syndrome

Sterling C. Johnson, Matthew D. Zammit, Patrick J. Lao, 2021, NeuroImage: Clinical.

White matter microstructure associations with episodic memory in adults with Down syndrome: a tract-based spatial statistics study

Sterling C. Johnson, Matthew D. Zammit, A. Alexander, 2021, Journal of Neurodevelopmental Disorders.

Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation

Sterling C. Johnson, Patrick J. Lao, W. Klunk, 2018, Brain Imaging and Behavior.

In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer’s disease dementia to young controls

B. Christian, H. Rowley, T. Betthauser, 2018, bioRxiv.

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age

Sterling C. Johnson, B. Christian, H. Rowley, 2019, Brain : a journal of neurology.

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

Sterling C. Johnson, K. Blennow, O. Hansson, 2023, JAMA neurology.

Intracranial vascular flow oscillations in Alzheimer’s disease from 4D flow MRI

Sterling C. Johnson, David R. Rutkowski, Kevin M. Johnson, 2020, NeuroImage: Clinical.

Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers

Sterling C. Johnson, Kevin M. Johnson, H. Rowley, 2021, Alzheimer's & dementia.

Leisure Activity, Brain β‐amyloid, and Episodic Memory in Adults with Down Syndrome

Patrick J. Lao, W. Klunk, O. Okonkwo, 2019, Developmental neurobiology.

Prescription Medications and Co-Morbidities in Late Middle-Age are Associated with Greater Cognitive Declines: Results from WRAP

Sterling C. Johnson, Kimberly D. Mueller, R. Koscik, 2022, Frontiers in Aging.

Associations between self-reported sleep patterns and health, cognition and amyloid measures: results from the Wisconsin Registry for Alzheimer’s Prevention

Sterling C. Johnson, D. Plante, Kimberly D. Mueller, 2023, Brain communications.

Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation

Patrick J. Lao, W. Klunk, J. Price, 2018, Brain Imaging and Behavior.

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology

Sterling C. Johnson, K. Blennow, A. Lleó, 2023, medRxiv.

Association of Sleep with Cognition and β -Amyloid Accumulation in Adults with Down Syndrome

Matthew D. Zammit, W. Klunk, K. Cody, 2020 .

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease

Sterling C. Johnson, O. Hansson, E. Jonaitis, 2023, Brain communications.

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

K. Blennow, A. Lleó, E. Vanmechelen, 2024, JAMA neurology.

Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD‐risk‐enriched cohorts

Kimberly D. Mueller, E. Jonaitis, S. Asthana, 2024, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors

E. Jonaitis, S. Janelidze, T. Betthauser, 2023, Brain communications.